Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene

David A. Nielsen, Robrina Walker, David P. Graham, Ellen M. Nielsen, Sara C. Hamon, Maureen Hillhouse, Dikla Shmueli-Blumberg, William B. Lawson, Kathy L Shores-Wilson, Beverlyn D. Settles-Reaves, John Rotrosen, Madhukar H. Trivedi, Andrew J. Saxon, Walter Ling, Thomas R. Kosten

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: The aim of this secondary analysis was to identify prodynorphin (PDYN) genetic markers moderating the therapeutic response to treatment of cocaine dependence with buprenorphine/naloxone (Suboxone®; BUP). Methods: Cocaine-dependent participants (N = 302) were randomly assigned to a platform of injectable, extended-release naltrexone (XR-NTX) and one of three daily medication arms: 4 mg BUP (BUP4), 16 mg BUP (BUP16), or placebo (PLB) for 8 weeks (Parent Trial Registration: Protocol ID: NIDA-CTN-0048, Clinical Trials.gov ID: NCT01402492). DNA was obtained from 277 participants. Treatment response was determined from weeks 3 to 7 over each 1-week period by the number of cocaine-positive urines per total possible urines. Results: In the cross-ancestry group, the PLB group had more cocaine-positive urines than the BUP16 group (P = 0.0021). The interactions of genetic variant × treatment were observed in the rs1022563 A-allele carrier group where the BUP16 group (N = 35) had fewer cocaine-positive urines (P = 0.0006) than did the PLB group (N = 26) and in the rs1997794 A-allele carrier group where the BUP16 group (N = 49) had fewer cocaine-positive urines (P = 0.0003) than did the PLB group (N = 58). No difference was observed in the rs1022563 GG or rs1997794 GG genotype groups between the BUP16 and PLB groups. In the African American-ancestry subgroup, only the rs1022563 A-allele carrier group was associated with treatment response. Conclusion: These results suggest that PDYN variants may identify patients who are best suited to treatment with XR-NTX plus buprenorphine for cocaine use disorder pharmacotherapy.

Original languageEnglish (US)
JournalEuropean Journal of Clinical Pharmacology
DOIs
StateAccepted/In press - 2022

Keywords

  • Buprenorphine
  • Cocaine
  • Gene
  • Polymorphism
  • Prodynorphin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene'. Together they form a unique fingerprint.

Cite this